UnitedHealth Group (UNH)

NYSEHealth CareMedical - Healthcare PlansSnapshot 2026-10-15

$401.43-1.29%

Close 2026-10-16 · 1-day change

Read the published Living FV report summary

Investment OutlookAs of Oct 15, 2026

What could strengthen or challenge UnitedHealth Group’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

+2.7%

+10% or more+5%0%−5%−10% or less

22.46 → 23.08 EPS · FY ending Dec 31, 2027 · 18 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 15, 2026 to Oct 15, 2026: (new ÷ prior − 1). Contributor count changed from 19 to 18; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Living FV™

Living Fair Value by QuarterlyIQ

A valuation that evolves as the business changes.

A published Living FV snapshot is not available yet. The valuation workflow remains discoverable; a market target cannot supply the missing evidence.

View Living FV report and workflow

What the Thesis Depends On

4 key conditions need to be met for the investment thesis to play out.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
AI investments generate at least $2 return per $1 spent	A supporting condition in UnitedHealth Group's published investment case. The stated target is >=2x ROI on AI spending.	Intact	AI investments fail to generate positive returns or reduce EPS	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
EPS at or above $17.35 in 2026	The company raised its 2026 EPS outlook to above $17.35 per share.	Intact	EPS falls below $17.35 in FY26	Diluted EPS: $4.56 per share FY2026-Q3; GAAP. Published target: >=17.35 USD per share. Target period is not explicitly aligned with this observation. Source published Oct 13, 20264.56 USD/share · source valueSource reportLast status assessment Oct 15, 2026 Measurement source consolidated · GAAP FY2026-Q3 · Period ending Sep 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q3. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Stable leadership without disruption to strategy	Leadership changes have been managed without disrupting operations.	Under Pressure	Leadership issues cause strategic or operational disruption	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
annual revenue growth of at least 1%	A primary condition in UnitedHealth Group's published investment case. The stated target is >=1% YoY.	Broken	annual revenue growth falls below 1% in FY26	Revenue growth: -0.41% FY2026-Q3; GAAP. Published target: >=1% YoY. Target period is not explicitly aligned with this observation. Source published Oct 13, 2026-0.412686 percent · calculatedSource reportLast status assessment Oct 15, 2026 Measurement source consolidated · GAAP FY2026-Q3 · Period ending Sep 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q3. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$23.08

$22.44 → $23.08 · observed estimates

FY2027 revenue$462.65B

$459.37B → $462.65B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$22.44	$459,373,226,520	27 / 23
2026-07-25	$22.44	$459,373,226,520	27 / 23
2026-07-26	$22.42	$459,240,852,138	19 / 19
2026-07-27	$22.44	$459,373,226,520	27 / 23
2026-07-28	$22.44	$459,373,226,520	27 / 23
2026-07-29	$22.44	$459,373,226,520	27 / 23
2026-07-30	$22.42	$459,240,852,138	19 / 19
2026-07-31	$22.42	$459,240,852,138	19 / 19
2026-08-01	$22.42	$459,240,852,138	19 / 19
2026-08-02	$22.44	$459,373,226,520	27 / 23
2026-08-03	$22.42	$458,627,470,977	19 / 19
2026-08-04	$22.42	$458,627,470,977	19 / 19
2026-08-05	$22.42	$458,627,470,977	19 / 19
2026-08-06	$22.42	$458,627,470,977	19 / 19
2026-08-08	$22.42	$458,627,470,977	19 / 19
2026-08-09	$22.44	$459,373,226,520	27 / 23
2026-08-10	$22.42	$458,627,470,977	19 / 19
2026-08-12	$22.42	$458,627,470,977	19 / 19
2026-08-13	$22.42	$458,627,470,977	19 / 19
2026-08-14	$22.42	$458,627,470,977	19 / 19
2026-08-15	$22.42	$458,627,470,977	19 / 19
2026-08-16	$22.42	$458,627,470,977	19 / 19
2026-08-17	$22.42	$458,627,470,977	19 / 19
2026-08-18	$22.42	$458,627,470,977	19 / 19
2026-08-19	$22.42	$458,627,470,977	19 / 19
2026-08-20	$22.42	$458,616,421,447	19 / 19
2026-08-21	$22.42	$458,616,421,447	19 / 19
2026-08-22	$22.42	$458,616,421,447	19 / 19
2026-08-23	$22.42	$458,616,421,447	19 / 19
2026-08-24	$22.42	$458,616,421,447	19 / 19
2026-08-25	$22.45	$458,616,419,994	19 / 19
2026-08-26	$22.45	$458,616,419,994	19 / 19
2026-08-27	$22.45	$458,616,419,994	19 / 19
2026-08-28	$22.45	$458,616,419,994	19 / 19
2026-08-29	$22.45	$458,616,431,535	19 / 19
2026-08-30	$22.45	$458,616,431,535	19 / 19
2026-08-31	$22.45	$458,616,431,535	19 / 19
2026-09-01	$22.45	$458,616,431,535	19 / 19
2026-09-02	$22.45	$458,616,431,535	19 / 19
2026-09-03	$22.45	$458,616,436,635	19 / 19
2026-09-04	$22.45	$458,616,436,635	19 / 19
2026-09-05	$22.45	$458,616,431,535	19 / 19
2026-09-06	$22.45	$458,616,431,535	19 / 19
2026-09-07	$22.45	$458,616,431,535	19 / 19
2026-09-08	$22.45	$458,616,431,535	19 / 19
2026-09-09	$22.45	$458,616,431,535	19 / 19
2026-09-10	$22.45	$458,616,431,535	19 / 19
2026-09-11	$22.45	$458,616,431,535	19 / 19
2026-09-12	$22.45	$458,616,431,535	19 / 19
2026-09-13	$22.45	$458,616,431,535	19 / 19
2026-09-14	$22.45	$458,616,431,535	19 / 19
2026-09-15	$22.46	$458,533,098,202	19 / 19
2026-09-16	$22.46	$458,533,098,203	18 / 18
2026-09-17	$22.52	$458,533,098,203	18 / 18
2026-09-18	$22.52	$458,533,098,203	18 / 18
2026-09-19	$22.52	$458,533,098,203	18 / 18
2026-09-20	$22.52	$458,533,098,203	18 / 18
2026-09-21	$22.52	$458,533,098,203	18 / 18
2026-09-22	$22.52	$458,533,098,203	18 / 18
2026-09-23	$22.52	$458,533,098,203	18 / 18
2026-09-24	$22.52	$458,533,098,203	18 / 18
2026-09-25	$22.52	$459,218,223,203	18 / 18
2026-09-26	$22.52	$459,218,223,203	18 / 18
2026-09-27	$22.63	$459,218,223,203	18 / 18
2026-09-28	$22.63	$459,218,223,203	18 / 18
2026-09-29	$22.63	$459,218,223,203	18 / 18
2026-09-30	$22.63	$459,218,223,203	18 / 18
2026-10-01	$22.63	$459,218,223,203	18 / 18
2026-10-02	$22.63	$459,218,223,203	18 / 18
2026-10-03	$22.63	$459,218,223,203	18 / 18
2026-10-04	$22.63	$459,218,223,203	18 / 18
2026-10-05	$22.63	$459,218,223,203	18 / 18
2026-10-06	$22.63	$459,207,806,536	18 / 18
2026-10-07	$22.63	$459,207,806,536	18 / 18
2026-10-08	$22.63	$459,207,806,536	18 / 18
2026-10-09	$22.63	$459,207,806,536	18 / 18
2026-10-10	$22.63	$459,207,806,536	18 / 18
2026-10-11	$22.62	$459,207,806,536	18 / 18
2026-10-12	$22.62	$459,207,720,804	18 / 18
2026-10-13	$22.62	$459,207,720,804	18 / 18
2026-10-14	$22.96	$462,259,147,057	18 / 17
2026-10-15	$23.08	$462,648,605,391	18 / 18

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	23	5	1
2026-06-01	23	5	1
2026-07-01	23	5	1
2026-08-01	23	5	0
2026-09-01	23	4	0
2026-10-01	22	4	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 22 Buy / Strong Buy · 4 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades5 maintains

Recent actions · Sep 16–Oct 15 · 5 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Raymond JamesOct 15

$450.00New observation · no comparable prior

Robert W. BairdOct 14 · prior Jul 16

$453.00 → $427.00-5.7%

Piper SandlerOct 14 · prior Jul 16

$477.00 → $504.00+5.7%

BarclaysOct 14 · prior Jul 20

$441.00 → $440.00-0.2%

New StreetOct 9

$402.00New observation · no comparable prior

$0$277.20$554.40

1 raises · 2 cuts · 0 unchanged · 2 without a comparable prior

How this is measured

Sep 16, 2026–Oct 15, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

AI investments generate at least $2 return per $1 spentDirect metric needs a verified mapping
EPS at or above $17.35 in 2026Diluted EPS: $4.56 per share
Stable leadership without disruption to strategyPublished status: Under Pressure
annual revenue growth of at least 1%Published status: Broken

Next proof point

Next earnings date unavailable

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.1%Typical daily move · historical

Downside history

-28.5%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

UnitedHealth Group outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 10, 2026

What kind of bet this is

This investment represents a durable compounder with a focus on healthcare services. The current thesis state is intact, supported by strong recent financial performance despite some mixed signals in execution and sector conditions.

What's priced into UnitedHealth Group

The market appears to have priced in a neutral valuation, reflecting a low expectations gap. UNH is seen as relatively cheap compared to its peers, suggesting that the current valuation does not fully reflect its potential.

What the fundamentals likely do

Management is focused on raising earnings per share (EPS) guidance and improving operating margins, with recent results showing strong performance in these areas. However, there are mixed signals regarding revenue growth in its Optum business, which could impact overall performance.

What UnitedHealth Group hinges on

The thesis hinges on maintaining credibility in guidance and the performance of sector bellwethers like CVS and ELV. Additionally, the impact of macroeconomic factors, such as job growth and recession fears, could influence UNH's performance.